Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132817) titled 'Clinical Study on the Titration Treatment of Patients with Moderate to Severe Cancer Pain Using Oxybutynin Naloxone Extended-Release Tablets' on Sept. 18.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shandong Provincial Hospital (Shandong Children's Hospital)
Condition:
Moderate to severe cancer pain
Intervention:
Control group (Oxycodone sustained-release tablets):Starting dose: 20mg every 12 hours. Dose adjustment: The investigator adjusts the study drug dose every 24 hours based on pain control and adverse reactions. (1) Dose escalation: During treatment, if NRS >= 4 or brea...